The Chinese Center for Disease Control and Prevention (CDC) has announced that coronavirus vaccines from China could be ready for global use before November. The Asian giant has four promising COVID-19 vaccines at final levels of clinical trials, and three of these have been administered in July to various segments of the Chinese population under the country’s emergency use laws.
CDC chief biosafety expert, Guizhen Wu, revealed that the drugs are currently undergoing Phase 4 clinical trials and they would be ready for worldwide administration before November, or the latest in December. She added that she had received one of the drugs herself in April and had experienced no alarming side effects since she took them several months back.
The Chinese chief biosafety expert did not however reveal which of the four potential vaccines she took or got administered with.
Three of the vaccines are manufactured by Sinopharm (China National Pharmaceutical Group) and Sinovac Biotech; the fourth candidate is manufactured by CanSino Biologics. The one by CanSino Biologics was endorsed by the Chinese government for use by the military in June. Sinopharm revealed that its vaccines would complete the Phase 3 trials shortly and ready for public administration by November.
Given that over 925,000 people had perished from COVID-19 since it started in January this year, major pharmaceutical companies around the world have been racing against themselves to develop effective coronavirus vaccines that will halt the infection and spread of the pandemic.
Major drugmakers in the West have vowed to run through the entire gamut of clinical trials without minding how long they take in order to produce safe and effective vaccines; they said they will not allow themselves to be stampeded with any political pressures or interference that could undermine the integrity of standard scientific procedures in developing the COVID-19 vaccines.